Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.46 |
| ▸ | DRD4 | P21917 | 2/20 | 0.45 |
| ▸ | HTR2A | P28223 | 2/20 | 0.45 |
| ▸ | TP53 | P04637 | 4/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | HTR2C | P28335 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.38 |
| ▸ | XIAP | P98170 | 1/20 | 0.38 |
| ▸ | KHK | P50053 | 1/20 | 0.37 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6811475 | 1.00 | MAPT (0.46) | MAPTDRD4HTR2ATP53THRB | |
| SCHEMBL13200493 | 0.85 | DRD4 (0.45) | MAPTDRD4HTR2ATP53THRB | |
| SCHEMBL5088742 | 0.82 | XIAP (0.38) | MAPTTP53HTR2CLMNAALDH1A1 | |
| SCHEMBL2966951 | 0.81 | MAPT (0.48) | MAPTDRD4HTR2ATP53THRB | |
| Hydrochloric Acid SCHEMBL6220144 | 0.80 | MAPT (0.47) | MAPTDRD4HTR2ATP53THRB | |
| SCHEMBL5631643 | 0.76 | XIAP (0.45) | MAPTHTR2CLMNAALDH1A1HSD11B1 | |
| SCHEMBL14922244 | 0.76 | ALDH1A1 (0.48) | MAPTHTR2CLMNAALDH1A1HSD11B1 | |
| SCHEMBL5631645 | 0.76 | XIAP (0.45) | MAPTHTR2CLMNAALDH1A1HSD11B1 | |
| SCHEMBL6811380 | 0.76 | HTR2C (0.44) | MAPTHTR2CLMNAALDH1A1HSD11B1 | |
| SCHEMBL2968890 | 0.76 | MAPT (0.50) | MAPTDRD4HTR2ATP53THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040122001-A1 | Pharmaceutical compounds | ELI LILLY AND COMPANY | 2004-06-24 | — | — | US | disclosed |
| EP-1345930-A2 | PHARMACEUTICAL COMPOUNDS | ELI LILLY AND COMPANY (US) | 2003-09-24 | — | — | EP | disclosed |
| WO-2002050067-A2 | PHARMACEUTICAL HETEROCYCLIC COMPOUNDS | ELI LILLY AND COMPANY (US) | 2002-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040122001-A1 | Pharmaceutical compounds | CYP2D6, LPXN, CYP1B1 | MAPT 2401/4885DRD4 715/4885HTR2A 2038/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.